Abstract:Objective To explore the role of the pyrin domain-containing 3 ( NLRP3) inflammasome in advanced glycation end products ( AGEs )-induced mice pancreatic β-cell damage. Methods AGEs were administered intraperitoneally for 6 weeks in NLRP3 knockout mice or C57BL/6J mice. Intraperitoneal glucose tolerance test and insulin releasing test were performed. Pancreatic sections were stained with haematoxylin and eosin, or with F4/80 and NLRP3 antibodies. Insulin and pancreatic tissue monocyte chemotactic protein 1 ( MCP-1) as well as interleukin-1β( IL-1β) levels were measured with ELISA kits. Expression of MCP-1 protein was determined by western blot. MIN6 cells and mouse peritoneal macrophages cells were treated with AGEs and different interventions (antioxidant NAC, adenovirus NLRP3 shRNA or NLRP3 knockout). Reactive oxygen species production, NLRP3 mRNA expression, IL-1β secretion, caspase 1 activity, apoptosis and glucose stimulated insulin release were determined. Results Injection of AGEs induced an abnormal response to glucose, enhanced the insulitis score, and increased the levels of pancreatic tissue MCP-1 and IL-1β, as well as raised the expression of NLRP3 and F4/80 in pancreatic islet. Remarkably, co-localization of NLRP3 and macrophage marker F4/80 was observed in islet. The damages were improved in NLRP3 knockout mice. After incubation with AGEs, reactive oxygen species production and cell apoptosis was enhanced, NLRP3 inflammasome activated, with glucose-stimulated insulin release impaired in MIN6 cells. NAC treatment alliviated the above damages, but NLRP3 gene silencing had no effect on ROS level, apoptosis, and insulin secretion. Finally NAC treatment and NLRP3 gene knockout inhibited activation of NLRP3 inflammasome induced by AGEs in mouse peritoneal macrophages cells. Conclusion NLRP3 knockout ameliorates the islet β-cell damage induced by AGEs. These effects were associated with AGEs-induced islets macrophage infiltrating by up-regulation of MCP-1 expression, and AGEs-induced activation of NLRP3 inflammasome in macrophage through ROS pathway, which results in the release of active IL-1βand leads to the lesions of β-cell.

Activation of NLRP3 Inflammasome by Advanced Glycation End Products Promotes Pancreatic Islet Damage

On the Effects of NLRP3 Inflammasome on Mice Pancreatic Β-Cell Damage Induced by Advanced Glycation End Products

Insulin-Attenuated Inflammatory Response of Dendritic Cells in Diabetes by Regulating RAGE-PKCβ1-IRS1-NF-κB Signal Pathway: A Study on the Anti-Inflammatory Mechanism of Insulin in Diabetes

The effect of AGEs on NADPH oxidase expression in the process of islet injuring

Advanced glycation end products activated endothelial-to-mesenchymal transition in pancreatic islet endothelial cells and triggered islet fibrosis in diabetic mice

AGEs and chronic subclinical inflammation in diabetes: disorders of immune system.

Advanced Glycation End Products (ages) Induce Apoptosis of Fibroblasts by Activation of NLRP3 Inflammasome Via Reactive Oxygen Species (ROS) Signaling Pathway.

NLRP3 inflammasome links vascular senescence to diabetic vascular lesions

Advanced Glycation End Products Impair Glucose-Stimulated Insulin Secretion of a Pancreaticβ-Cell Line INS-1-3 by Disturbance of Microtubule Cytoskeleton Via P38/mapk Activation

Matrix Metalloproteinase 2 Contributes To Pancreatic Beta Cell Injury Induced By Oxidative Stress

Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes

Advanced Glycation End-Products Acting as Immunomodulators for Chronic Inflammation, Inflammaging and Carcinogenesis in Patients with Diabetes and Immune-Related Diseases

The Effect Of Nlrp Inflammasome On The Regulation Of Ages-Induced Inflammatory Response In Human Periodontal Ligament Cells

Inhibiting Receptor for Advanced Glycation End Product (age) and Oxidative Stress Involved in the Protective Effect Mediated by Glucagon-Like Peptide-1 Receptor on Age Induced Neuronal Apoptosis

Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy

High Glucose and Lipopolysaccharide Prime NLRP3 Inflammasome via ROS/TXNIP Pathway in Mesangial Cells.

Nlrp3 Activation In Endothelia Promotes Development Of Diabetes-Associated Atherosclerosis

Activation of the NLRP3 inflammasome by RAC1 mediates a new mechanism in diabetic nephropathy

Diabetes Aggravates Acute Pancreatitis Possibly Via Activation of NLRP3 Inflammasome in Db/db Mice

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development